Discovery of the first nonpeptidic, Small-molecule, highly selective somatostatin receptor subtype 5 antagonists: A chemogenomics approach

Journal of Medicinal Chemistry

Volumn 50, Issue 25, 2007, Pages 6291-6294

  Martin, Rainer E ^a   Green, Luke G ^a   Guba, Wolfgang ^a   Kratochwil, Nicole ^a   Christ, Andreas ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; DOPAMINE RECEPTOR; FLUSPIRILENE; HISTAMINE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; LOPERAMIDE; OPIATE RECEPTOR; SEROTONIN RECEPTOR; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN RECEPTOR 5 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL GENETICS; DRUG BINDING SITE; DRUG STRUCTURE; DRUG SYNTHESIS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ASTEMIZOLE; BENZOXAZOLES; BINDING SITES; HISTAMINE H1 ANTAGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; PIPERIDINES; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37049020280     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701143p     Document Type: Article

References (27)

1. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179, 77-79.
2. Reisine, T.; Bell, G. I. Molecular biology of somatostatin receptors. Endocrinol. Rev. 1995, 16, 427-442.
3. Gillies, G. Somatostatin: the neuroendocrine story. Trends Pharmacol. Sci. 1997, 18, 87-95.
4. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Failie, D. P. Beta-strand mimetics. Chem. Rev. 2004, 104, 6085-6117.
5. Pittaluga, A.; Feligioni, M.; Longordo, F.; Arvigo, M.; Raiteri, M. Somatostatin-induced activation and up-regulation of N-methyl-D- aspartate receptor function: Mediation through calmodulin-dependent protein kinase II, phospholipase C, protein kinase C, and tyrosine kinase in hippocampal noradrenergic nerve endings. J. Pharmacol. Exp. Ther. 2005, 313, 242-249.
6. Ösapay, G.; Ösapay, K. Therapeutic applications of somatostatin analogues. Expert Opin. Ther. Pat. 1998, 8, 855-870.
7. Rajeswaran, W. G.; Hocart, S. J.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J. Med. Chem. 2001, 44, 1305-1311.
8. Hannon, J. P.; Nunn, C.; Stolz, B.; Bruns, C.; Weckbecker, G.; Lewis, I.; Troxler, T.; Hurth, K.; Hoyer, D. Drug design at peptide receptors. J. Mol. Neurosci. 2002, 18, 15-27.
9. Souers, A. J.; Virgilio, A. A.; Rosenquist, A.; Fenuik, W.; Ellman, J. A. Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of β-turn mimetic libraries. J. Am. Chem. Soc. 1999, 121, 1817-1825.
10. Sciciński, J. J.; Barker, M. D.; Murray, P. J.; Jarvie, E. M. The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor. Bioorg. Med. Chem. Lett. 1998, 8, 3609-3614.
11. Rohrer, S. P.; Birzin, E. T.; Mosley, R. T.; Berk, S. C.; Hutchins, S. M.; Shen, D.-M.; Xiong, Y.; Hayes, E. C.; Parmar, R. M.; Foor, F.; Mitra, S. W.; Degrado, S. J.; Shu, M.; Klopp, J. M.; Cai, S.-J.; Blake, A.; Chan, W. W. S.; Pasternak, A.; Yang, L.; Patchett, A. A.; Smith, R. G.; Chapman, K. T.; Schaeffer, J. M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282, 737-740.
12. Bruns, C.; Lewis, I.; Briner, U.; Meno-Tetang, G.; Weckbecker, G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 2002, 146, 707-716.
13. Contour-Galcéra, M.-O.; Sidhu, A.; Plas, P.; Roubert, P. 3-Thio-1,2,4-triazoles, novel somatostatin SST2/SST5 agonists. Bioorg. Med. Chem. Lett. 2005, 15, 3555-3559.
14. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
15. Stahl, M.; Guba, W.; Kansy, M. Integrating molecular design resoures within modern drug discovery research: the Roche experience. Drug Discovery Today 2006, 11, 326-333.
16. Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M. Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr. Opin. Chem. Biol. 2004, 8, 287-296.
17. Kratochwil, N. A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoener, M. C.; Mühlemann, A.; Porter, R. H. P.; Stahl, M.; Gerber, P. R. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. J. Chem. Inf. Model. 2005, 45, 1324-1336.
18. Frimurer, T. M.; Ulven, T.; Elling, C. E.; Gerlach, L.-O.; Kostenis, E.; Högberg, T. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett. 2005, 15, 3707-3712.
19. LOPAC = Library of Pharmacologically Active Compounds. See Web site: www.sigmaaldrich.com.
20. BioPrint is a registered trademark of Cerep SA. See Web site: www.cerep.com.
21. Oppenheimer, J. J.; Casale, T. B. Next generation antihistamines: therapeutic rationale, accomplishments and advances. Expert Opin. Invest. Drugs 2002, 11, 807-817.
22. Gao, K.; Muzina, D.; Gajwani, P.; Calabreses, J. R. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J. Clin. Psychiatry 2006, 67, 1327-1340.
23. Heel, R. C.; Brogden, R. N.; Speightz, T. M.; Avery, G. S. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978, 15, 33-52.
24. Anaya de Parrodi, C.; Quintero-Cortés, L.; Sandoval- Ramírez, J. A short synthesis of astemizole. Synth. Commun. 1996, 26, 3323-3329.
25. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artifical membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 1998, 41, 1007-1010.
26. + channel blockers. J. Med. Chem. 2002, 45, 3844-3853.
27. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: highlights and hangups. J. Med. Chem. 2006, 49, 5029-5046.